Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases

There are several antibody therapeutics in preclinical and clinical development, industry-wide, for the treatment of central nervous system (CNS) disorders. Due to the limited permeability of antibodies across brain barriers, the quantitative understanding of antibody exposure in the CNS is importan...

Descripción completa

Detalles Bibliográficos
Autores principales: Bloomingdale, Peter, Bakshi, Suruchi, Maass, Christian, van Maanen, Eline, Pichardo-Almarza, Cesar, Yadav, Daniela Bumbaca, van der Graaf, Piet, Mehrotra, Nitin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604880/
https://www.ncbi.nlm.nih.gov/pubmed/34378151
http://dx.doi.org/10.1007/s10928-021-09776-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604880/
https://www.ncbi.nlm.nih.gov/pubmed/34378151
http://dx.doi.org/10.1007/s10928-021-09776-7

Ejemplares similares